Structure Therapeutics (GPCR) Stock Price, News & Analysis $61.87 +2.01 (+3.36%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$58.94▼$62.8550-Day Range$47.95▼$74.3052-Week Range$20.80▼$75.02Volume348,461 shsAverage Volume751,290 shsMarket Capitalization$2.87 billionP/E RatioN/ADividend YieldN/APrice Target$81.14 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Structure Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside31.2% Upside$81.14 Price TargetShort InterestHealthy8.11% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.86) to ($0.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.91 out of 5 starsMedical Sector543rd out of 933 stocksPharmaceutical Preparations Industry246th out of 431 stocks 3.5 Analyst's Opinion Consensus RatingStructure Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $81.14, Structure Therapeutics has a forecasted upside of 31.2% from its current price of $61.87.Amount of Analyst CoverageStructure Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted8.11% of the float of Structure Therapeutics has been sold short.Short Interest Ratio / Days to CoverStructure Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Structure Therapeutics has recently decreased by 2.92%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldStructure Therapeutics does not currently pay a dividend.Dividend GrowthStructure Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GPCR. Previous Next 2.9 News and Social Media Coverage News SentimentStructure Therapeutics has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Structure Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Structure Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Structure Therapeutics insiders have not sold or bought any company stock.Percentage Held by Institutions46.12% of the stock of Structure Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Structure Therapeutics are expected to decrease in the coming year, from ($0.86) to ($0.98) per share. Previous Next See Top Rated MarketRank™ Stocks Here About Structure Therapeutics Stock (NASDAQ:GPCR)Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.Read More GPCR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GPCR Stock News HeadlinesDecember 3, 2023 | americanbankingnews.comStructure Therapeutics (NASDAQ:GPCR) Shares Gap Up to $55.69December 2, 2023 | americanbankingnews.comAnalysts Set Structure Therapeutics Inc. (NASDAQ:GPCR) Price Target at $81.14December 10, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 30, 2023 | morningstar.comStructure Therapeutics Inc ADRNovember 29, 2023 | finance.yahoo.com11 Best Young Stocks to Buy and Hold For 20 YearsNovember 17, 2023 | msn.comStructure Therapeutics files to sell 24M shares for holdersNovember 16, 2023 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)November 15, 2023 | finanznachrichten.deStructure Therapeutics Inc.: Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent HighlightsDecember 10, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 15, 2023 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About Structure TherapeuticsNovember 15, 2023 | msn.comStructure Therapeutics GAAP EPS of -$0.21 beats by $0.01November 14, 2023 | finance.yahoo.comStructure Therapeutics Reports Third Quarter 2023 Financial Results and Recent HighlightsNovember 5, 2023 | morningstar.comStructure Therapeutics Inc ADR GPCR Stock QuoteOctober 19, 2023 | markets.businessinsider.com4 Analysts Have This to Say About Structure TherapeuticsOctober 19, 2023 | markets.businessinsider.comBuy Rating on Structure Therapeutics: Leveraging GLP-1 Drugs for Chronic Diseases and Obesity with High Potential Asset GSBR-1290October 13, 2023 | markets.businessinsider.comPiper Sandler Sticks to Its Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)October 6, 2023 | finance.yahoo.comStructure Therapeutics (GPCR) Stock Up 9% This Week: Here's WhyOctober 3, 2023 | seekingalpha.comStructure Therapeutics: Tipping The Scales In Obesity ManagementOctober 2, 2023 | finance.yahoo.comWhy Shares of Structure Therapeutics Are Up MondaySeptember 30, 2023 | msn.comStructure Therapeutics surges as early data from obesity pill tops expectationsSeptember 30, 2023 | msn.comStructure Therapeutics surges after early-stage data for oral weight loss agentSeptember 30, 2023 | msn.comGLP-1 drug developer Carmot Therapeutics reportedly mulling IPO or buyoutSeptember 29, 2023 | msn.comLeerink sees Structure Therapeutics stock as "undervalued"September 29, 2023 | finance.yahoo.comStructure Soars 35% As Newcomer Takes On Behemoths Lilly, Novo In Obesity TreatmentSeptember 29, 2023 | finanznachrichten.deStructure Therapeutics Inc.: Structure Therapeutics Announces $300 Million Private Placement Equity FinancingSeptember 29, 2023 | msn.comStructure's Obesity Pill Could Challenge Lilly, Novo, Small Study SuggestsSeptember 29, 2023 | reuters.comStructure Therapeutics surges on promising early stage obesity drug dataSee More Headlines Receive GPCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Structure Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today12/10/2023Fiscal Year End12/31/2023Next Earnings (Estimated)4/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GPCR CUSIPN/A CIK1888886 Webwww.structuretx.com Phone628-229-9277FaxN/AEmployees87Year FoundedN/APrice Target and Rating Average Stock Price Target$81.14 High Stock Price Target$97.00 Low Stock Price Target$33.00 Potential Upside/Downside+31.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-58.26% Return on Assets-38.93% Debt Debt-to-Equity RatioN/A Current Ratio10.45 Quick Ratio10.45 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares46,390,000Free FloatN/AMarket Cap$2.87 billion OptionableNot Optionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Raymond C. Stevens Ph.D. (Age 59)CEO & Director Comp: $747.33kDr. Yingli Ma Ph.D. (Age 49)Chief Technology Officer Comp: $497.58kDr. Mark A. Bach M.D. (Age 66)Ph.D., Chief Medical Officer Comp: $628.37kMr. Jun S. Yoon (Age 45)Co- Founder, CFO & Secretary Dr. Xichen Lin Ph.D. (Age 49)Chief Scientific Officer Mr. Tony PengSenior Vice President of LegalMr. Bob GatmaitanSenior Vice President of PeopleDr. Hui Lei Ph.D.Senior Vice President of ChemistryDr. Fang Zhang Ph.D.Executive VP & Head of BiologyMs. Lani IbarraSenior Vice President of Clinical Development OperationsMore ExecutivesKey CompetitorsOrganon & Co.NYSE:OGNAmphastar PharmaceuticalsNASDAQ:AMPHMoonLake ImmunotherapeuticsNASDAQ:MLTXPrestige Consumer HealthcareNYSE:PBHCorcept TherapeuticsNASDAQ:CORTView All CompetitorsInstitutional OwnershipWellington Management Group LLPBought 657,310 shares on 12/1/2023Ownership: 1.870%Adage Capital Partners GP L.L.C.Bought 1,607,525 shares on 11/15/2023Ownership: 4.703%The Manufacturers Life Insurance Company Bought 14,455 shares on 11/15/2023Ownership: 0.144%Acuta Capital Partners LLCBought 5,000 shares on 11/15/2023Ownership: 0.013%Tower Research Capital LLC TRC Bought 854 shares on 11/14/2023Ownership: 0.002%View All Institutional Transactions GPCR Stock Analysis - Frequently Asked Questions Should I buy or sell Structure Therapeutics stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Structure Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GPCR shares. View GPCR analyst ratings or view top-rated stocks. What is Structure Therapeutics' stock price target for 2024? 7 equities research analysts have issued 12 month target prices for Structure Therapeutics' shares. Their GPCR share price targets range from $33.00 to $97.00. On average, they expect the company's stock price to reach $81.14 in the next year. This suggests a possible upside of 31.2% from the stock's current price. View analysts price targets for GPCR or view top-rated stocks among Wall Street analysts. How have GPCR shares performed in 2023? Structure Therapeutics' stock was trading at $26.00 on January 1st, 2023. Since then, GPCR shares have increased by 138.0% and is now trading at $61.87. View the best growth stocks for 2023 here. When is Structure Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our GPCR earnings forecast. How were Structure Therapeutics' earnings last quarter? Structure Therapeutics Inc. (NASDAQ:GPCR) announced its earnings results on Tuesday, November, 14th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.01. What ETFs hold Structure Therapeutics' stock? ETFs with the largest weight of Structure Therapeutics (NASDAQ:GPCR) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Fidelity Disruptive Medicine ETF (FMED). When did Structure Therapeutics IPO? (GPCR) raised $150 million in an IPO on Friday, February 3rd 2023. The company issued 10,740,000 shares at $13.00-$15.00 per share. Who are Structure Therapeutics' major shareholders? Structure Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Adage Capital Partners GP L.L.C. (4.70%), FMR LLC (4.16%), Federated Hermes Inc. (2.90%), Wellington Management Group LLP (1.87%), Monashee Investment Management LLC (1.66%) and Avidity Partners Management LP (1.31%). How do I buy shares of Structure Therapeutics? Shares of GPCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:GPCR) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.